The International Society For Antiviral Research (ISAR)
The Society was organized in 1987 as a non-profit scientific organization for the purpose of advancing and disseminating knowledge in all areas of antiviral research. To achieve this objective, the Society organizes an annual meeting. The Society is now in its thirty-first year of existence, and has more than 300 members representing 30 countries. Membership application forms will be available at the Conference Registration desk, or from our website at www.isar-icar.com.
Contributors
Confirmed Sponsors as of May 28, 2018

**PLATINUM**
Gilead Sciences
Foster City, CA, USA

**GOLD**
Janssen – Pharmaceutical companies of Johnson & Johnson
Beerse, Belgium

**SILVER**
AbbVie
North Chicago, IL, USA

Burroughs Wellcome Fund
Research Triangle Park, NC, USA

Chimerix
Durham, NC, USA

Emergent BioSolutions
Gaithersburg, MD, USA

JCR Pharmaceutical Co.
Ashiya, Japan

Southern Research Institute
Birmingham, AL, USA

**BRONZE**
ACS Infectious Diseases
Washington, DC, USA

AiCuris Anti-infective Cures
Wuppertal, Germany

Antiva Biosciences
South San Francisco, CA, USA

Elsevier
Amsterdam, The Netherlands

Institute for Antiviral Research,
Utah State University
Logan, UT, USA

Oxeltis
Montpellier, France

Quanterix
Lexington, MA, USA

Riboscience
Sunnyvale, CA, USA

Sanofi
Paris, France

Toyama Chemical Co.
Tokyo, Japan

Viroclinics Biosciences
Rotterdam, The Netherlands

ViroVet
Leuven, Belgium

XpressBio
Frederick, MD, USA

**ADDITIONAL GRANT FUNDING PROVIDED BY:**
The EU H2020 ANTIVIRALS Consortium*

*The ANTIVIRALS consortium has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 642434.*
KEYNOTE ADDRESSES

Monday, June 11, 2018

Epidemic Arboviral Diseases: Implications for Research and Public Health Infrastructure
Annelies Wilder-Smith
Umeå University, Sweden and WHO, Geneva
3:45 PM
ARCHIVE HALL I

Hepatitis C Virus: Problem Solved. And Now?
Jean-Michel Pawlotsky
University of Paris-Est
4:30 PM
ARCHIVE HALL I

NETWORKING EVENTS

Monday, June 11, 2018

Women in Science Roundtable
12:00 PM – 1:45 PM
NOBLE HALL

Opening Reception
6:45 PM – 8:00 PM
NOBLE HALL

Wednesday, June 13, 2018

New Member and First Time Attendee Networking featuring a PechaKucha Competition
12:30 PM – 1:30 PM
INFANTE HALL

Career Development Panel
1:45 PM – 2:45 PM
INFANTE HALL

Thursday, June 14, 2018

Closing Reception and Banquet
7:00 PM
FERREIRA CELLARS
(Advance purchase of banquet ticket required; transportation from select hotels provided)
### Schedule at a Glance

#### MONDAY, JUNE 11, 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM – 6:30 PM</td>
<td>Registration</td>
<td>ARCHIVE HALL FOYER</td>
</tr>
<tr>
<td>12:00 PM – 1:45 PM</td>
<td>Women in Science Roundtable</td>
<td>NOBLE HALL</td>
</tr>
<tr>
<td>2:00 PM – 3:45 PM</td>
<td>Satellite Workshop of the EU H2020 Consortium ‘ANTIVIRALS’</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>3:45 PM – 5:15 PM</td>
<td>Welcome and Keynote Addresses</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td></td>
<td>Jean-Michel Pawlotsky and Annelies Wilder-Smith</td>
<td></td>
</tr>
<tr>
<td>5:15 PM – 5:45 PM</td>
<td>Coffee Break</td>
<td>RIBEIRA</td>
</tr>
<tr>
<td>5:45 PM – 6:35 PM</td>
<td>Recent Technological Advances Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>6:45 PM – 8:00 PM</td>
<td>Opening Reception</td>
<td>NOBLE HALL</td>
</tr>
<tr>
<td></td>
<td><em>Light hors d’oeuvres served</em></td>
<td></td>
</tr>
</tbody>
</table>

#### TUESDAY, JUNE 12, 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 5:30 PM</td>
<td>Registration</td>
<td>ARCHIVE HALL FOYER</td>
</tr>
<tr>
<td>8:30 AM – 9:00 AM</td>
<td>Women in Science Award Lecture</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>9:00 AM – 10:00 AM</td>
<td>Virus Evolution Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>10:00 AM – 10:30 AM</td>
<td>Coffee Break</td>
<td>RIBEIRA</td>
</tr>
<tr>
<td>10:30 AM – 12:15 PM</td>
<td>Emerging Infections Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>12:15 PM – 1:30 PM</td>
<td>Lunch <em>Available for purchase</em></td>
<td>NOBLE HALL</td>
</tr>
<tr>
<td></td>
<td><em>Light hors d’oeuvres served</em></td>
<td></td>
</tr>
<tr>
<td>1:30 PM – 2:35 PM</td>
<td>Influenza Virus Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>2:35 PM – 3:15 PM</td>
<td>Coffee Break</td>
<td>RIBEIRA</td>
</tr>
<tr>
<td>3:15 PM – 5:00 PM</td>
<td>Respiratory Viruses Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>5:00 PM – 7:00 PM</td>
<td>Poster Session 1</td>
<td>ARCHIVE HALL II</td>
</tr>
<tr>
<td></td>
<td><em>Light hors d’oeuvres served</em></td>
<td></td>
</tr>
</tbody>
</table>
## WEDNESDAY, JUNE 13, 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 2:30 PM</td>
<td>Registration</td>
<td>ARCHIVE HALL FOYER</td>
</tr>
<tr>
<td>8:30 AM – 9:00 AM</td>
<td>Antonín Holý Memorial Award Lecture</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>9:00 AM – 9:10 AM</td>
<td>Antiviral Research: Annual Journal Summary</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>9:10 AM – 10:00 AM</td>
<td>Viral Hepatitis Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>10:00 AM – 10:30 AM</td>
<td>Coffee Break</td>
<td>RIBEIRA</td>
</tr>
<tr>
<td>10:30 AM – 12:15 PM</td>
<td>Hepatitis and Retroviruses Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>12:30 PM – 1:30 PM</td>
<td>New Member and First Time Attendee Networking featuring a PechaKucha Competition</td>
<td>INFANTE HALL</td>
</tr>
<tr>
<td>1:45 PM – 2:45 PM</td>
<td>Career Development Panel&lt;br&gt;Snacks and beverages served</td>
<td>INFANTE HALL</td>
</tr>
</tbody>
</table>

## THURSDAY, JUNE 14, 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 5:00 PM</td>
<td>Registration</td>
<td>ARCHIVE HALL FOYER</td>
</tr>
<tr>
<td>8:15 AM – 9:00 AM</td>
<td>Gertrude Elion Memorial Award Lecture</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>9:00 AM – 10:30 AM</td>
<td>Cytomegalovirus Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>10:30 AM – 11:00 AM</td>
<td>Coffee Break</td>
<td>RIBEIRA</td>
</tr>
<tr>
<td>11:00 AM – 12:15 PM</td>
<td>Medicinal Chemistry Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>12:15 PM – 12:30 PM</td>
<td>Annual ISAR Business Meeting</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>12:30 PM – 1:30 PM</td>
<td>Lunch&lt;br&gt;Available for purchase</td>
<td>NOBLE HALL</td>
</tr>
<tr>
<td>1:30 PM – 2:00 PM</td>
<td>William Prusoff Young Investigator Award Lecture</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>2:00 PM – 3:45 PM</td>
<td>HIV Treatment and Cure Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>3:45 PM – 5:45 PM</td>
<td>Poster Session 2&lt;br&gt;Light hors d’oeuvres served</td>
<td>ARCHIVE HALL II</td>
</tr>
<tr>
<td>7:00 PM – 10:30 PM</td>
<td>Closing Reception &amp; Banquet&lt;br&gt;*Advance purchase of banquet ticket required&lt;br&gt;Transportation provided from select hotels</td>
<td>FERREIRA CELLARS</td>
</tr>
</tbody>
</table>
## FRIDAY, JUNE 15, 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 12:00 PM</td>
<td>Registration</td>
<td>ARCHIVE HALL FOYER</td>
</tr>
<tr>
<td>8:30 AM – 9:00 AM</td>
<td>Shotgun Oral Presentations</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>9:00 AM – 10:30 AM</td>
<td>Emerging Infections and Clinical Evaluation of Antivirals Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>10:30 AM – 11:00 AM</td>
<td>Coffee Break</td>
<td>RIBEIRA</td>
</tr>
<tr>
<td>11:00 AM – 12:30 PM</td>
<td>DNA Viruses and Emerging Viruses Session</td>
<td>ARCHIVE HALL I</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Conference Concludes</td>
<td></td>
</tr>
</tbody>
</table>
**MONDAY, JUNE 11th, 2018**

**Satellite Workshop of the EU H2020 Consortium “Antivirals”**  
2:00 PM – 3:45 PM

ANTIVIRALS, a European Training Network to Train the Next Generation of Experts in Antiviral Drug Development  
Frank van Kuppeveld, Ph.D.  
Virology Division, Dept. of Infectious Diseases & Immunology, Utrecht University, Utrecht, The Netherlands

13-14 ESRs  
Shotgun Presentation Session

How an Old Dog Performs New Tricks: Mechanistic Insight into the Mode of Action of Fluoxetine Targeting Enterovirus 2CATPase  
Lisa Bauer, M.S.  
Virology Division, Faculty of Veterinary Medicine, Utrecht University, The Netherlands

Heteroarylpyrimidine (HAP) and Novel Non-HAP Capsid Assembly Modifiers Show Differences in their Mode of Action In Vitro  
Angelica Corcuera, M.S.  
AiCuris Anti-Infective Cures GmbH, Wuppertal, Germany

**Welcome and Keynote Addresses**  
3:45 PM – 5:15 PM

Epidemic Arboviral Diseases: Implications for Research and Public Health Infrastructure  
Annelies Wilder-Smith, M.D., Ph.D.  
Umeå University Sweden and WHO, Geneva, Umeå, Sweden

Hepatitis C Virus: Problem Solved. And Now?  
Jean-Michel Pawlotsky, M.D., Ph.D.  
University of Paris-Est, Paris, France

**Coffee Break**  
5:15 PM – 5:45 PM

**Opening Reception**  
6:45 PM – 8:00 PM

**TUESDAY, JUNE 12TH, 2018**

**Women in Science Award Lecture**  
8:30 AM – 9:00 AM

Making the Invisible Visible: Arbovirus Transmission, Risk, Disease and Prevention in Kenya  
A. Desiree LaBeaud, M.D., M.S.  
Pediatric Infectious Diseases, Stanford University, Stanford, CA, United States of America

**Virus Evolution Session**  
9:00 AM – 10:00 AM

Getting to the Root of Epidemic Spread: An Evolutionary Perspective on Pathogen Emergence  
Philippe Lemey, Ph.D.  
Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium

Monitoring, Predicting and Altering the Evolution of RNA Virus Populations  
Marco Vignuzzi, Ph.D.  
Institut Pasteur, Paris, France

**Coffee Break**  
10:00 AM – 10:30 AM

**Emerging Infections Session**  
10:30 AM – 12:15 PM

Ebola Treatment: Working in the Dark Under the Spotlight  
Sir Michael Jacobs, Ph.D.  
Royal Free London NHS Foundation Trust, London, United Kingdom

Alpha-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication  
Rolf Hilgenfeld, Ph.D.  
Institute of Biochemistry & German Center for Infection Research (DZIF), University of Luebeck, Luebeck, Germany

Mutagenesis of the Human Genome to Study Virus Entry  
Thijn Brummelkamp, Ph.D.  
Netherlands Cancer Institute, Dept. of Biochemistry, Amsterdam, The Netherlands
Therapeutic Treatment of Zika Virus Infection Using a Brain-Penetrating Antiviral Peptide
Nam-Joon Cho, Ph.D.
Materials Science and Engineering Nanyang Technological University, Singapore, Singapore

Reverse Genetics Identifies Chikungunya Virus nsP1 as the Target for a Novel Nucleoside Analogue
Kristina Kovacikova, B.S.
Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands

Strategies of Tick-Borne Encephalitis Virus to Escape from Nucleoside Analogue-Mediated Inhibition
Ludek Eyer, Ph.D.
Department of Virology, Veterinary Research Institute, Brno, Czechia

Role of Nonstructural Protein 1 in the Replication Cycle of Dengue Virus
Anna Plaszczyszka, M.S.
Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany

In Vivo Replication of Human Norovirus in Zebrafish Larvae
Jana Van Dycke, M.S.
KU Leuven – Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium, Leuven, Belgium

Lunch: Noble Hall 12:15 PM – 1:30 PM

**Influenza Virus Session**
1:30 PM – 2:35 PM

Passive Antibody Therapies Against Endemic, Emerging and Re-Emerging Viral Infectious Diseases
Davide Corti, Ph.D.
Humabs BioMed, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland

Influenza Virus Infection, Neuraminidase Inhibitor Treatment, and Emergence of Drug Resistance in an Immunocompromised Ferret Model
Ron Fouchier, Ph.D.
Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands

**Coffee Break**  2:35 PM – 3:15 PM

**Respiratory Viruses Session**
3:15 PM – 5:00 PM

Treatment Options for Human RSV: Small Molecules, Antibodies or Something in Between?
Xavier Saelens
VIB Center for Medical Biotechnology, Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium

Differential Antiviral Activities of RSV Inhibitors in Human Airway Epithelium
Carmen Mirabelli, Ph.D.
KU Leuven, Leuven, Belgium

Treatment of an EV-D68 Infection with Human Intravenous Immunoglobulin (hIVIG) in a Respiratory and Neurological Model in AG129 Mice
Brett Hurst, M.S.
Utah State University, Logan, Utah, United States of America

Antiviral and Immunological Adjuvant Efficacy of Synthetic RNA as a RIG-I Agonist against Influenza A Virus Infection
Meehyein Kim, Ph.D.
Virus Research Group, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea

The Host-Targeted Iminosugar UV-4B Inhibits Influenza Virus without Selecting for Resistance
Lisa Evans DeWald, Ph.D.
Emergent BioSolutions

**Poster Session 1**
5:00 PM – 7:00 PM
5:00–6:00 PM: ODD numbered poster presentations
6:00–7:00 PM: EVEN numbered poster presentations

**Wednesday, June 13th, 2018**

**Antonín Holý Memorial Award Lecture**
8:30 AM – 9:00 AM

From Nucleoside Monophosphate Prodrugs to Nucleoside Triphosphate Prodrugs – The Challenge, a Possible Solution and Further Improvements
Chris Meier, Ph.D.
University of Hamburg, Hamburg, Germany
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM – 9:10 AM</td>
<td>Antiviral Research: Annual Journal Summary</td>
</tr>
<tr>
<td>Mike Bray</td>
<td></td>
</tr>
<tr>
<td>9:10 AM – 10:00 AM</td>
<td>Viral Hepatitis Session</td>
</tr>
<tr>
<td></td>
<td>Hbc and CAMs: a Tale of &quot;Swiss-Knife&quot; Protein and Antivirals</td>
</tr>
<tr>
<td></td>
<td>David Durantel, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>Cancer Research Centre of Lyon (CRCL), INSERM, U1052, UMR_5286 CNRS/University of Lyon, Lyon, France</td>
</tr>
<tr>
<td></td>
<td>Mechanisms of Immune Dysfunction in Chronic Hepatitis B and Possible Immune Therapies</td>
</tr>
<tr>
<td></td>
<td>Percy Knolle, M.D.</td>
</tr>
<tr>
<td></td>
<td>Institute of Molecular Immunology and Experimental Oncology, Technische Universitaet Muenchen, Muenchen, Germany</td>
</tr>
<tr>
<td></td>
<td>Coffee Break 10:00 – 10:30 AM</td>
</tr>
<tr>
<td>10:30 AM – 12:15 PM</td>
<td>Hepatitis and Retroviruses Session</td>
</tr>
<tr>
<td></td>
<td>Pharmacological Inhibition of CDK4/6 Enhances Antiviral and Cytotoxic Activity of Antimetabolites</td>
</tr>
<tr>
<td></td>
<td>Eva Riveira-Muñoz, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>Irsicaixa AIDS Research Institute, Badalona, Spain</td>
</tr>
<tr>
<td></td>
<td>ADAR1 is a Regulator of Innate and Antiviral Immune Function in HCV infection.</td>
</tr>
<tr>
<td></td>
<td>María Pujantell, B.S.</td>
</tr>
<tr>
<td></td>
<td>IrsiCaixa AIDS Research Institute, Badalona, Spain</td>
</tr>
<tr>
<td></td>
<td>The NEDD8-Activating Enzyme Inhibitor MLN4924 Potently Inhibits Transcription from Covalently Closed Circular DNA in a Hepatitis B Virus X Protein-Dependent Manner</td>
</tr>
<tr>
<td>Bingqian Qu, M.S.</td>
<td>Molecular Virology, Department of Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany</td>
</tr>
<tr>
<td></td>
<td>Hepatitis B Virus Replication Inhibition by N-hydroxypyridinediones and N-hydroxysoquinolinediones in Culture through Inhibition of the Viral Ribonuclease H</td>
</tr>
<tr>
<td>Tiffany Edwards, M.S.</td>
<td>Saint Louis University, St. Louis, Missouri, United States of America</td>
</tr>
<tr>
<td>12:30 PM – 1:30 PM</td>
<td>New Member and First Time Attendee Networking featuring a PechaKucha Competition</td>
</tr>
<tr>
<td></td>
<td>Career Development Panel 1:45 PM – 2:45 PM</td>
</tr>
<tr>
<td>8:15 AM – 9:00 AM</td>
<td>Gertrude Elion Memorial Award Lecture</td>
</tr>
<tr>
<td></td>
<td>Quantitative Studies of HCMV in a Human Challenge Model</td>
</tr>
<tr>
<td>Paul Griffiths, M.D.</td>
<td>Centre for Virology, University College London Medical School, London, United Kingdom</td>
</tr>
<tr>
<td>9:00 AM – 10:30 AM</td>
<td>Cytomegalovirus Session</td>
</tr>
<tr>
<td></td>
<td>Neurodevelopmental Sequelae Following Congenital CMV: Role of Virus-Induced Inflammation</td>
</tr>
<tr>
<td>William Britt, M.D.</td>
<td>Departments of Pediatrics, Microbiology, and Neurobiology; School of Medicine, University of Alabama, Birmingham, Alabama, United States of America</td>
</tr>
<tr>
<td></td>
<td>Treatment of Congenital CMV Infection: New Populations, New Regimens, and New Drugs?</td>
</tr>
<tr>
<td>David Kimberlin, M.D.</td>
<td>University of Alabama, Birmingham, Alabama, United States of America</td>
</tr>
<tr>
<td></td>
<td>Letermovir: Current State of the Art</td>
</tr>
<tr>
<td>Randi Leavitt, M.D., Ph.D.</td>
<td>Clinical Research, MSD, North Wales, Pennsylvania, United States of America</td>
</tr>
<tr>
<td>10:30 AM – 11:00 AM</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
### Medicinal Chemistry Session
11:00 AM – 12:15 PM

- Synthesis and Evaluation of Mono-, Di-, and Tetra-acylated Prodrugs of IHVR-19029  
  Nicky Hwang, B.S.  
  *Baruch S. Blumberg Institute*

- A Novel Chemotype as Hepatitis B Virus Capsid Assembly Effectors  
  Zhengqiang Wang, Ph.D.  
  *University of Minnesota*

- Mimicking the HRB Region of RSV F Protein as Antiviral Strategy  
  Roberto Manganaro, M.S.  
  *Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff, United Kingdom of Great Britain and Northern Ireland*

- Discovery of novel small-molecule inhibitors against chikungunya virus: virtual screening, organic synthesis and cell-based mode of action studies  
  Birgit Zonsics, M.S.  
  *School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom, Cardiff, Wales, United Kingdom of Great Britain and Northern Ireland*

- Rational Design and Synthesis of Novel Potential Inhibitors of Zika Virus Replication Targeting the NS5 Methyltransferase  
  Marcella Bassetto, Ph.D.  
  *Cardiff University*

- Gamma-Non-Symmetrically-Modified d4T Triphosphates as Anti-HIV Prodrugs  
  Chenglong Zhao, M.S.  
  *University of Hamburg, Hamburg, Germany*

### ISAR Business Meeting *(all are welcome to attend)*
12:15 PM – 12:30 PM

- President: José Esté, Ph.D.  
- Treasurer: Brian Gowen, Ph.D.  
- Secretary: Graciela Andrei, Ph.D.

**Lunch: Noble Hall**  
12:30 PM – 1:30 PM

### HIV Treatment and Cure Session
2:00 PM – 3:45 PM

- Transcriptional Profiling of HIV Latency  
  Angela Ciuffi, Ph.D.  
  *Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland*

- Identification of a Capsid-Binding Protein that Recognizes the Nuclear HIV Capsid to Promote CGAS-Mediated Innate Immune Activation in Dendritic Cells  
  Nicolas Manel, Ph.D.  
  *Institut Curie, PSL Research University, Paris, France*

- Strategies for an HIV Cure: Early Lessons from Shock and Kill Trials  
  Ole Schmeltz Søgaard, M.D., Ph.D.  
  *Dept. of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark*

### Poster Session 2
3:45 PM – 5:45 PM

- 3:45–4:45 PM: EVEN numbered poster presentations
- 4:45–5:45 PM: ODD numbered poster presentations

### Closing Reception
Ferreira Cellars  
7:00 PM – 10:30 PM

*Advance purchase of banquet ticket required.  
Transportation provided from select hotels.*

### Friday, June 15th, 2018

### Shotgun Poster Presentations
8:30 AM – 9:00 AM

### Emerging Infections and Clinical Evaluation of Antivirals Session
9:00 AM – 10:30 AM

- Chemical Genetic Studies Revealed a Novel Mechanism of Innate Immune Evasion by Yellow Fever Virus NS4B That Can Be Targeted by an Antiviral Compound  
  Xuexiang Zhang, M.S.  
  *Baruch S. Blumberg Institute*

- Identification of a Novel Small Molecule Inhibitor of Lassa Fever Virus Entry that Targets the Viral Receptor, LAMP1  
  May Wang, B.S.  
  *Harvard Medical School; Brigham and Women’s Hospital, Boston, Massachusetts, United States of America*
Labyrinthopeptin A1 Exerts Broad-Spectrum Antiviral Activity Against Dengue and Zika Virus
Merel Oeyen, M.S.
Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Belgium

The therapeutic human bispecific neutralizing antibody FIT-1 treats congenital Zika disease
Justin Julander, Ph.D.
Institute for Antiviral Research, Utah State University, Logan, Utah, United States of America

Towards the development of direct-acting antivirals for the treatment of human parechoviruses infections
Kristina Lanko, M.S.
KU Leuven, Rega Institute for Medical Research, Leuven, Belgium

CMX521: A Nucleoside with Pan-Genotypic Activity against Norovirus
Randall Lanier, Ph.D.
Chimerix, Durham, North Carolina, United States of America

Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Haematopoietic Cell Transplant Recipients
Cameron Douglas, Ph.D.
Infectious Disease Research, Merck & Co., Inc., Kenilworth, New Jersey, United States of America

Coffee Break  10:30 AM – 11:00 AM

DNA Viruses and Emerging Viruses Session
11:00 AM – 12:30 PM

Broad Spectrum Virucidal Non-toxic Strategies
Valeria Cagno, Ph.D.
University of Geneva and EPFL, Geneva, Switzerland

Metabolic Activation of MBX-2168 Involves Enzymatic Removal of a Butyl-Ether Moiety by Adenosine Deaminase-Like Protein 1
Brian Gentry, Ph.D.
Drake University College of Pharmacy and Health Sciences, Des Moines, Iowa, United States of America

A Novel Class of Tryptophan Dendrimers Binds to the 5-fold Vertex of Enterovirus A71 Capsid and Blocks Virus Entry
Liang Sun, M.S.
Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium

A Host-Targeting Antiviral Inhibitor, STF1019, Provides Protection Against Enterovirus 71 Infection in a Mouse Model
E. Bart Tarbet, Ph.D.
Institute for Antiviral Research, Utah State University, Logan, Utah, United States of America

Identification of Small Chemical Compounds Blocking Tegumentation and Assembly of Herpes Simplex Virus
Julio Cesar Villalvazo Guerrero, M.S.
Institute of Virology, Hannover Medical School

The Innovative Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication
Dana Wolf, M.D.
Hadassah University Hospital, The Lautenberg Center for General and Tumor Immunology, Jerusalem, Israel

Closing Remarks